Hudson Regional LTC Pharmacy now carries Journavx (suzetrigine), a newly approved medication that represents an entirely new class of non-opioid pain treatments. This development offers important new options for managing acute pain in individuals with intellectual and developmental disabilities.

FDA Approval and What It Means

Approved by the U.S. Food and Drug Administration in January 2025, Journavx is indicated for the treatment of moderate to severe acute pain in adults. It's the first medication in more than two decades to introduce a new mechanism for treating acute pain, representing a significant advancement in pain management science.

For healthcare providers working with individuals with intellectual and developmental disabilities, new pain management options are particularly valuable. This population often faces challenges in pain assessment and management due to communication barriers, making safe and effective pain medications essential.

How Journavx Works Differently

Unlike opioid medications, which act on receptors in the brain and spinal cord, Journavx works in the peripheral nervous system. It targets specific sodium channels involved in pain signaling, helping prevent pain messages from reaching the brain.

This unique mechanism offers several potential advantages:

Reduced Risk of Dependence: Because Journavx doesn't act on the same brain receptors as opioids, it doesn't carry the same risks of physical dependence or addiction.

Different Side Effect Profile: The peripheral mechanism may result in fewer central nervous system side effects compared to traditional pain medications.

Non-Opioid Alternative: For individuals with I/DD who may be at higher risk of adverse effects from opioids, having non-opioid options for acute pain management is clinically valuable.

Appropriate Uses for Journavx

Journavx is indicated specifically for acute pain—short-term pain resulting from injury, surgery, or other medical procedures. Appropriate scenarios might include:

• Post-surgical recovery pain
• Injury-related pain (fractures, sprains, trauma)
• Acute dental pain following procedures
• Other short-term moderate to severe pain conditions

It's important to note that Journavx is not intended for chronic pain management. For individuals with intellectual and developmental disabilities experiencing ongoing pain conditions, comprehensive pain management plans developed with healthcare providers remain the appropriate approach.

Pain Assessment Challenges in the I/DD Population

One of the most significant challenges in providing appropriate pain management for individuals with intellectual and developmental disabilities is accurate pain assessment. Many individuals cannot verbally communicate their pain levels or describe pain characteristics.

Care teams must rely on behavioral indicators such as:

• Changes in facial expressions or vocalizations
• Altered sleep patterns
• Decreased participation in usual activities
• Increased agitation or aggression
• Changes in eating patterns
• Guarding or protecting specific body areas
• Unusual postures or movement patterns

Having effective pain management options like Journavx becomes especially important when pain assessment itself presents challenges. When providers can confidently prescribe non-opioid medications for acute pain, it reduces the risks associated with potentially over-relying on opioid medications in situations where pain levels are difficult to assess precisely.

The Opioid Crisis and I/DD Populations

The national opioid crisis has affected all populations, including individuals with intellectual and developmental disabilities. Research indicates that people with I/DD may face unique vulnerabilities related to opioid use, including:

• Difficulty understanding medication risks and proper use
• Challenges recognizing and reporting side effects
• Potential for medication mismanagement by others
• Limited access to addiction treatment services designed for people with I/DD

Expanding non-opioid pain management options specifically addresses these concerns by providing effective alternatives that don't carry the same risks.

Clinical Considerations for I/DD Care Providers

Healthcare providers considering Journavx for individuals with intellectual and developmental disabilities should evaluate:

Individual Health History: As with any medication, complete medical history including liver and kidney function, other medications, and previous medication responses should inform prescribing decisions.

Duration of Need: Since Journavx is indicated for acute pain, providers should have clear expectations about the anticipated duration of treatment.

Monitoring and Follow-up: Regular assessment of pain levels (using appropriate tools for individuals with communication limitations) and medication effectiveness should guide ongoing treatment.

Care Team Communication: Ensuring that all members of an individual's support team—including residential staff, day program providers, and family members—understand the medication's purpose and what to monitor.

What This Advancement Means for I/DD Healthcare

The development of medications like Journavx represents important progress in pain management. For too long, the primary options for moderate to severe acute pain have been opioid medications or less effective alternatives. Having a new class of non-opioid pain medication expands the clinical toolkit available to providers.

For individuals with intellectual and developmental disabilities specifically, any advancement that offers effective treatment with reduced risks deserves attention. Pain management should never force providers to choose between inadequate pain control and medications that carry significant risks.

Moving Forward with Better Options

The approval of Journavx doesn't solve all pain management challenges, but it represents meaningful progress. As research continues and clinical experience with this medication grows, the I/DD healthcare community will develop better understanding of how and when this option serves individuals best.

Pain management for people with intellectual and developmental disabilities requires thoughtful, individualized approaches that balance effectiveness with safety. New medications like Journavx expand the possibilities for achieving that balance.

For more information about Journavx or other pain management options available through Hudson Regional LTC Pharmacy, contact the pharmacy team directly.

---